Log In
BCIQ
Print this Print this
 

KU-046

  Manage Alerts
Collapse Summary General Information
Company Kareus Therapeutics S.A.
DescriptionCombination of a generally recognized as safe (GRAS) molecule combined with a marketed non-Alzheimer's disease product using Kareus' Karlect technology
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard IndicationAlzheimer's disease (AD)
Indication DetailsTreat Alzheimer's disease (AD)
Regulatory Designation
PartnerQuintiles Transnational Holdings Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

05/03/2016

Undisclosed

0

0

Get a free BioCentury trial today